This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.
We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.
Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.
We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.
Terms of use
Privacy Notice
System cookies (required)
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
Google Analytics
This is a web analytics service.
Processing company
Google Ireland Limited
Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
Marketing
Advertisement
Web Analytics
Technologies Used
Cookies
Pixel Tags
Data Attributes
IP address (anonymised)
Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
IP address
Date and time of visit
Usage data
Click path
App updates
Browser information
Device information
JavaScript support
Pages visited
Referrer URL
Downloads
Flash version
Location information
Purchase activity
Widget interactions
Legal Basis
In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
Art. 6 (1) (a) GDPR
Location of Processing
Republic of Serbia
Retention Period
The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
Alphabet Inc.
Facebook Pixel
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
Facebook Ireland Limited
4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
advertising
Marketing
Retargeting
Analyse
Tracking
Technologies Used
Cookies
Data Attributes
Pixel specific data
Http-Header
Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
Facebook user ID
Browser information
Usage data
Geräteinformationen
Non-sensitive custom data
Referrer URL
Pixel ID
Location information
Pixel specific data
User behaviour
Ads viewed
Interactions with advertisement, services, and products
Marketing information
Content viewed
IP address
Legal Basis
In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
Republic of Serbia
Retention Period
The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
Facebook Inc.
ENG
SRB
DEU
Home
About us
Business
Products
Responsibility
Career
Media
Blog
Contact
ENG
SRB
DEU
Home
About us
▾
Company profile
Mission and vision
Management
Employees
Representative offices
Production
Our history
Business
▾
R&D
Quality
Stakeholders
Code of Conduct
General conditions of business operations
Products
▾
Report adverse drug reactions
Responsibility
▾
Compliance
Social responsibility
Sustainable development
Career
▾
Corporate culture
Education of employees
Your career
Media
Blog
Contact
Home
›
Media
›
News
›
62 years of Hemofarm’s business leadership
62 years of Hemofarm’s business leadership
09. December 2022.
Hemofarm has continued its growth journey also in 2022, ending the year with exceptional business results, as shared at a cocktail party hosted by the regional pharmaceutical industry leader for friends, business partners and associates. Hemofarm has celebrated 62 years of successful operation, emphasizing that good health of everyone is the core mission of the company and its greatest asset.
The biggest success in 2022 is related to successful operation in an extremely demanding environment, in which Hemofarm managed to deliver all necessary products to all markets where STADA Group operates, in the required quantity and the inherent quality. Since 2006, STADA Group has invested more than 400 million EUR in Hemofarm.
‘Focusing on growth, innovations, and operational excellence, we keep on developing Hemofarm as a modern and responsible company. Following the roadmap of sustainable development, we continue along a not so well-trodden and simple path, which is nevertheless our absolute priority. We will keep on aspiring to contribute to the sustainable development of the entire society through Hemofarm’s progress and development. Business-wise, we have continued pursuing our ascending trajectory. We are finishing this year with 306 million of produced packs, accounting for a 6.8% year-on-year growth. As one of the biggest German investors, we have continued with the investments. In 2022, around 25 million EUR have been invested in strategic projects within Hemofarm Group. Our portfolio has kept on growing during 2022, and most importantly, we are the local and regional market leader in sustainable development and the most determined fighter for people's health’, said Dr Ronald Seeliger, CEO of Hemofarm, adding that Hemofarm has preserved the leadership position in both the market of Serbia, and Bosnia and Herzegovina.
According to him, Hemofarm is not only the leader in pharmaceutical industry, but also a pioneer of sustainable, smart, and responsible business in this region.
The 10th jubilee Sustainable Development Report
has also been published this year. Holding over 70% of total exports of pharmaceuticals from the country, Vršac-based company is simultaneously the major Serbian exporter of medicines. It operates on four continents and comprises a team of about 4000 employees. Hemofarm is present on almost 40 markets all around the world and it is one of the top pharmaceutical manufacturers in this region.
‘In addition to all successes, we are particularly proud of Hemofarm Foundation which will celebrate its 30th anniversary next year. Its perseverance in the fight for people’s health is the proof that commitment and faith in wellbeing of everyone can change the world and make a better place for all of us to live in‘, Seeliger pointed out on this occasion.